Sanjivani Paranteral Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q3 FY26.
SP

Sanjivani Paranteral Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Sanjivani Paranteral Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹21Cr
+20.2% YoY
+34.6% QoQ
Net profit
₹3Cr
+37.9% YoY
+59.8% QoQ
Margin
17.26%
+2.6 pp YoY
+2.7 pp QoQ

Sanjivani Paranteral Ltd Q3 FY26 key numbers

Revenue
SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.

As stated in Sanjivani Paranteral Ltd's Q3 FY26 earnings call transcript · published 14 Aug 2026. Reported figures, not investment advice.

Price₹193
Market cap₹235 Cr
P/E35.2

The short version

FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).

From Sanjivani Paranteral Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
  • SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
  • Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
  • Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
  • Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
  • Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
  • Export markets to continue being key revenue drivers, contributing ~77% of total revenue.

2 more points from Sanjivani Paranteral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Major capex cycle is currently over; all plants are operational.
  • FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
  • No significant new capex expected in FY '27 beyond this recurring amount.
  • Future growth is expected from ramp-up and approvals rather than large new investments.

2 more points from Sanjivani Paranteral Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • It indicates strong growth driven primarily by export markets and product mix improvements.
  • The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
  • The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
  • Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28.

Sanjivani Paranteral Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Sanjivani Paranteral Ltd Q3 FY26 results — key figures

Sanjivani Paranteral Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue2117+20.2%16+34.6%
Operating profit (EBITDA)43+41.2%2+60%
Operating margin17.26%14.7%+2.6 pp14.52%+2.7 pp
Profit before tax33+39%2+59.4%
Net profit (PAT)32+37.9%2+59.8%
EPS (₹)2.131.60+33.1%1.34+59%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sanjivani Paranteral Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sanjivani Paranteral Ltd Q3 FY26 results?

FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).

What is Sanjivani Paranteral Ltd share price analysis?

Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sanjivani Paranteral Ltd planning capital expenditure?

Major capex cycle is currently over; all plants are operational.

Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.